Table 3.
Changes in liver weight and serum and hepatic fractions in all groups of rats.
| Parameter | STD | Control + EA | Control + EA + CC | T1DM | T2DM + EA | T1DM + EA + CC |
|---|---|---|---|---|---|---|
| Serum | ||||||
| TGs (mg/dl) | 46.2 ± 6.7 | 35.2 ± 4.1a | 49.8 ± 7.1b | 121.1 ± 9.8abc | 61.4 ± 6.3abcd | 129 ± 8.1abce |
| CHOL (mg/dl) | 78.3 ± 7.8 | 61.2 ± 7.1a | 83.5 ± 9.1b | 173 ± 15.4abc | 73.4 ± 9.2bd | 181 ± 13.9abce |
| LDL-c (mg/dl) | 36.5 ± 5.6 | 22.6 ± 4.7a | 40.3 ± 7.5b | 83.5 ± 7.4abc | 43.5 ± 6.9abd | 88.3 ± 8.5abce |
| FFAs (µmol/l) | 135 ± 15.4 | 110 ± 13.4a | 143 ± 17.4b | 372 ± 24.5abc | 222 ± 12.6abcd | 355 ± 31.3abce |
| Liver | ||||||
| Triglycerides (µg/g) | 724 ± 88.9 | 609 ± 48.4a | 812 ± 73.4b | 3823 ± 413abc | 1092 ± 112abcd | 3293 ± 318abce |
| CHOL (µg/g) | 218 ± 18.6 | 178 ± 14.4a | 231 ± 22.1b | 518 ± 49.2abc | 265 ± 34.2abcd | 539 ± 41.5abce |
| FFA (µmol/g) | 43.2 ± 6.8 | 33.2 ± 4.4a | 49.3 ± 7.3b | 132 ± 18.4ab | 83.3 ± 8.8abcd | 147 ± 15.6abce |
Data are presented as the mean ± SD for n = 8 rats/group. Significance was determined at p < 0.05. a: significantly different as compared to control; b: significantly different as compared to control + Ellagic acid (EA); c: significantly different as compared to control + EA + compound C (CC, and AMKP inhibitor); d: significantly different as compared to T1DM-induced rats; and e: significantly different as compared to T1DM + EA-treated rats.